• Media type: E-Article
  • Title: Incisional hernia after liver transplantation: mesh-based repair and what else?
  • Contributor: Perrakis, Aristotelis; Knüttel, Dagmar; Rahimli, Mirhasan; Andric, Mihailo; Croner, Roland S.; Vassos, Nikolaos
  • Published: Springer Science and Business Media LLC, 2021
  • Published in: Surgery Today, 51 (2021) 5, Seite 733-737
  • Language: English
  • DOI: 10.1007/s00595-020-02162-9
  • ISSN: 0941-1291; 1436-2813
  • Keywords: General Medicine ; Surgery
  • Origination:
  • Footnote:
  • Description: <jats:title>Abstract</jats:title><jats:sec> <jats:title>Purpose</jats:title> <jats:p>Incisional hernia (IH) is not uncommon after liver transplantation (LT). We investigated the long-term outcome of mesh-based hernia repair using an inlay-onlay technique.</jats:p> </jats:sec><jats:sec> <jats:title>Methods</jats:title> <jats:p>Our analysis was based on a prospective collected database of all LT recipients from our hospital over a period of 15 years. We analyzed clinical data including the period between LT and hernia development, the size and localization of the hernia, the length of in-hospital stay, immunosuppression, and postoperative morbidity, as well as follow-up data. The median follow-up period was 120 (range 12–200) months.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>Among a total of 220 patients who underwent a collective 239 LTs, 29 (13%) were found to have an IH after a median period of 27.5 months (range 3–96 months). There were 12 (41%) men and 17 (59%) women, with a median age of 51 years. The median size of the IH was 13 cm (range 2–30 cm) and the median in-hospital stay was 6 days. Mild postoperative complications developed in seven patients, including two onlay mesh infections. One patient (3.4%) suffered recurrence.</jats:p> </jats:sec><jats:sec> <jats:title>Conclusion</jats:title> <jats:p>Mesh-based hernia repair using the inlay/onlay technique represents an effective and safe method for patients with an IH after LT, without additional risk from continuous immunosuppression. </jats:p> </jats:sec>